Cantor Fitzgerald Comments on Alector FY2025 Earnings

Alector, Inc. (NASDAQ:ALEC - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Alector in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will earn ($2.55) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Alector's current full-year earnings is ($1.88) per share.

A number of other equities research analysts also recently issued reports on the stock. BTIG Research cut their price objective on shares of Alector from $16.00 to $5.00 and set a "buy" rating for the company in a research report on Tuesday, November 26th. Morgan Stanley cut shares of Alector from an "equal weight" rating to an "underweight" rating and decreased their target price for the stock from $10.00 to $3.00 in a research note on Tuesday, November 26th. HC Wainwright cut their price objective on shares of Alector from $35.00 to $7.00 and set a "buy" rating for the company in a report on Friday, November 29th. Mizuho downgraded shares of Alector from an "outperform" rating to a "neutral" rating and lowered their target price for the stock from $9.00 to $2.50 in a report on Tuesday, December 17th. Finally, Bank of America lowered shares of Alector from a "neutral" rating to an "underperform" rating and dropped their target price for the stock from $9.00 to $1.00 in a research report on Wednesday, December 4th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $3.75.

Alector Stock Up 2.9 %

Shares of NASDAQ ALEC traded up $0.05 during trading on Wednesday, reaching $1.78. 443,476 shares of the company traded hands, compared to its average volume of 788,975. The firm has a 50 day simple moving average of $2.46 and a 200-day simple moving average of $4.27. Alector has a 52-week low of $1.60 and a 52-week high of $7.58. The stock has a market capitalization of $174.32 million, a PE ratio of -1.05 and a beta of 0.57.

Alector (NASDAQ:ALEC - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.10. The company had revenue of $15.34 million during the quarter, compared to the consensus estimate of $16.33 million. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%.

Insider Activity

In other Alector news, insider Sara Kenkare-Mitra sold 26,500 shares of the company's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $2.52, for a total value of $66,780.00. Following the completion of the transaction, the insider now owns 565,215 shares in the company, valued at approximately $1,424,341.80. This represents a 4.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Arnon Rosenthal sold 52,172 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $2.52, for a total value of $131,473.44. Following the transaction, the chief executive officer now owns 2,507,074 shares in the company, valued at $6,317,826.48. This trade represents a 2.04 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 95,161 shares of company stock valued at $239,806. Company insiders own 9.10% of the company's stock.

Institutional Trading of Alector

Several large investors have recently bought and sold shares of ALEC. Rhumbline Advisers boosted its stake in shares of Alector by 20.1% in the second quarter. Rhumbline Advisers now owns 109,924 shares of the company's stock valued at $499,000 after purchasing an additional 18,398 shares during the period. Federated Hermes Inc. boosted its position in Alector by 4.1% in the 2nd quarter. Federated Hermes Inc. now owns 68,538 shares of the company's stock valued at $311,000 after buying an additional 2,709 shares during the period. Hsbc Holdings PLC grew its stake in shares of Alector by 84.5% in the second quarter. Hsbc Holdings PLC now owns 47,099 shares of the company's stock worth $208,000 after acquiring an additional 21,571 shares in the last quarter. XTX Topco Ltd increased its position in shares of Alector by 62.7% during the second quarter. XTX Topco Ltd now owns 31,069 shares of the company's stock worth $141,000 after acquiring an additional 11,978 shares during the period. Finally, Cubist Systematic Strategies LLC raised its stake in shares of Alector by 73.1% in the second quarter. Cubist Systematic Strategies LLC now owns 92,218 shares of the company's stock valued at $419,000 after acquiring an additional 38,947 shares in the last quarter. Hedge funds and other institutional investors own 85.83% of the company's stock.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.